Gene expression markers and treatment of multiple sclerosis
US12098426B2 · kind B2 · utility
0Cited by
43References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2021 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Dec 16, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.